Source link : https://newshealth.biz/health-news/canagliflozin-cv-benefits-appear-to-be-dose-dependent/
Cardiovascular benefits associated with the SGLT2 inhibitor drug canagliflozin appear to be dose-dependent, with benefits in some key clinical endpoints — including mortality — observed only in the higher of the two key doses of 300 mg and 100 mg of the drug, new research shows. “The benefit of canagliflozin on hard clinical endpoints may […]
The post Canagliflozin CV Benefits Appear to Be Dose-Dependent first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-06 17:00:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8